Kelun Pharmaceutical has several wholly-owned subsidiaries.

Kelun Pharmaceutical has 37 wholly-owned subsidiaries. They are: Yili Ning Chuan Biotechnology Co., Ltd., Kelun International Development Co., Ltd., Chongzhou Junjian Plastic Co., Ltd., Zhejiang Pharmaceutical Co., Ltd., Henan Kelun Pharmaceutical Co., Ltd., Chengdu Qingshan Likang Pharmaceutical Co., Ltd., Kelun Katz Pharmaceutical Co., Ltd., Guizhou Kelun Pharmaceutical Co., Ltd., etc.

First, Kelun Pharmaceutical

Ning Chuan Bio is the main production base of antibiotic intermediates in Kelun Pharmaceutical and one of the main suppliers of antibiotic intermediates in China. More than 30 key technologies for preparing antibiotic intermediates by microbial fermentation with independent intellectual property rights. The overall production and preparation technology of microbial fermentation antibiotic intermediates ranks first in China and has strong competitive advantages in domestic sub-industries. From 20 17 to 20 19, the biological net profit of Ning Chuan was-243 million yuan, 392 million yuan and 883,865,438+05 million yuan respectively, and the total liabilities were 5,705 million yuan, 5 14200 yuan and 5,452 million yuan respectively. Ning Chuan's biology has been reported and complained by the public for many times due to environmental problems, which has attracted media attention. Several times, he was ordered to stop production or even stop production for rectification, which made his project investment far exceed expectations and once fell into a state of loss.

Second, the spin-off listing

Kelun Pharmaceutical holds 88.49% of the shares of Ning Chuan Bio directly and indirectly, and is the controlling shareholder of Ning Chuan Bio. Liu Gexin, the controlling shareholder and actual controller of Kelun Pharmaceutical, is also the actual controller of Ning Chuan Bio. After the completion of this spin-off, the shareholding structure of Kelun Pharmaceutical will not change, and it still has the controlling stake in Ning Chuan Bio. Although the spin-off will lead to the dilution of Ning Chuan Bio shares held by Kelun Pharmaceutical, Kelun Pharmaceutical said that

To sum up, through this spin-off, Ning Chuan Bio will further broaden the financing channels, improve the overall financing efficiency of Kelun Pharmaceutical and reduce the overall asset-liability ratio. The growth of Ning Chuan's biological performance will also be reflected in the overall performance of Kelun Pharmaceutical, which is conducive to improving the company's overall profitability in the future.